PB2452

PhaseBio touts 'breakthrough' badge for bloodthinner reversal agent licensed from AstraZeneca, shares leap
Endpoints
Tue, 04/9/19 - 08:22 am
PhaseBio
Brilinta
PB2452
bloodthinner reversals
breakthrough status
AstraZeneca
PhaseBio details dollars in AstraZeneca deal as it rolls out a plan for $86M-plus IPO
Endpoints
Mon, 09/24/18 - 09:44 am
PhaseBio
IPOs
PB2452
anti-anti-coagulants
AstraZeneca